Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients

Piarulli, Francesco; Lapolla, Annunziata; Ragazzi, Eugenio; Susana, Angela; Sechi, Annalisa; Nollino, Laura; Cosma, Chiara; Fedele, Domenico; Sartore, Giovanni

doi:10.1016/j.atherosclerosis.2012.10.050

Cited by 29 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A review of the literature, however, shows that the current evidence regarding the association between sRAGE and vascular disease in diabetes is contradictory with at least one study showing that sRAGE concentrations are positively associated with coronary artery disease in patients with type 1 diabetes (21). Similarly, findings from studies of sRAGE concentrations in cardiovascular disease are also contradictory with reports showing either positive or negative associations (26,27). If sRAGE indeed plays a defensive role, diets with high concentrations of AGEs might elicit a response in terms of sRAGE concentrations in plasma; however, this has not been reported in the literature.…”

Section: Rage the Biology Of Rage Is Summarized Inmentioning

confidence: 81%

Dietary Advanced Glycation End Products and Their Role in Health and Disease

Uribarri

Castillo

Maza

et al. 2015

Advances in Nutrition

289

236

View full text Add to dashboard Cite

Over the past 2 decades there has been increasing evidence supporting an important contribution from food-derived advanced glycation end products (AGEs) to the body pool of AGEs and therefore increased oxidative stress and inflammation, processes that play a major role in the causation of chronic diseases. A 3-d symposium (1st Latin American Symposium of AGEs) to discuss this subject took place in Guanajuato, Mexico, on 1-3 October 2014 with the participation of researchers from several countries. This review is a summary of the different presentations and subjects discussed, and it is divided into 4 sections. The first section deals with current general knowledge about AGEs. The second section dwells on mechanisms of action of AGEs, with special emphasis on the receptor for advanced glycation end products and the potential role of AGEs in neurodegenerative diseases. The third section discusses different approaches to decrease the AGE burden. The last section discusses current methodologic problems with measurement of AGEs in different samples. The subject under discussion is complex and extensive and cannot be completely covered in a short review. Therefore, some areas of interest have been left out because of space. However, we hope this review illustrates currently known facts about dietary AGEs as well as pointing out areas that require further research.

show abstract

Section: Rage the Biology Of Rage Is Summarized Inmentioning

confidence: 81%

Dietary Advanced Glycation End Products and Their Role in Health and Disease

Uribarri

Castillo

Maza

et al. 2015

Advances in Nutrition

289

236

View full text Add to dashboard Cite

show abstract

“…Consistent with a previous report [32], the present study shows an inverse relation between serum esRAGE and hsCRP levels, supporting the notion that esRAGE protects against diabetic complication, in part through its anti-inflammatory effect. Recently, Piarulli et al found that esRAGE upregulation might be one of the antioxidant defenses for cells against atherosclerosis in patients with type 2 diabetes [33].…”

Section: Discussionmentioning

confidence: 99%

Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease

Yang¹,

Shen²,

Shen

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…esRAGE (endogenous secretory RAGE) formed by the alternative splicing of RAGE mRNA. Because of its ability to bind with the same ligands, sRAGE acts as a competitive inhibitor of RAGE and precludes the cell-bound RAGE signaling [19]. For this reason, many clinical studies have concluded the possibility of using sRAGE as a disease marker in such disorders [20, 21].…”

Section: Introductionmentioning

confidence: 99%

Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect

Haddad

Knani

Bouzidi³

et al. 2016

Disease Markers

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is considered one of the most important public health problems. Several and controversial studies showed that the role of advanced glycation end products (AGEs) and their receptor in the development of metabolic syndrome and therapeutic pathways is still unsolved. We have investigated whether plasma pentosidine, carboxymethyl-lysine (CML), and soluble receptor for advanced glycation end products (sRAGE) levels were increased in patients with MetS and the effect of metformin in plasma levels of pentosidine, CML, and sRAGE. 80 control subjects and 86 patients were included in this study. Pentosidine, CML, and sRAGE were measured in plasma by enzyme-linked immunosorbent assay (ELISA). Plasma pentosidine, CML, and sRAGE levels were significantly increased in patients compared to control subjects (P < 0.001, P < 0.001, and P = 0.014, resp.). Plasma levels of pentosidine were significantly decreased in patients who received metformin compared to untreated patients (P = 0.01). However, there was no significant difference between patients treated with metformin and untreated patients in plasma CML levels. Plasma levels of sRAGE were significantly increased in patients who received metformin and ACE inhibitors (P < 0.001 and P = 0.002, resp.). However, in a multiple stepwise regression analysis, pentosidine, sRAGE, and drugs treatments were not independently associated. Patients with metabolic syndrome showed increased levels of AGEs such as pentosidine and CML. Metformin treatment showed a decreased level of pentosidine but not of CML. Therapeutic pathways of AGEs development should be taken into account and further experimental and in vitro studies merit for advanced research.

show abstract

Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients

Cited by 29 publications

References 34 publications

Dietary Advanced Glycation End Products and Their Role in Health and Disease

Dietary Advanced Glycation End Products and Their Role in Health and Disease

Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease

Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect

Contact Info

Product

Resources

About